PMID- 27997009
OWN - NLM
STAT- MEDLINE
DCOM- 20180508
LR  - 20190221
IS  - 2038-1840 (Electronic)
IS  - 0034-1193 (Linking)
VI  - 107
IP  - 12
DP  - 2016 Dec
TI  - [Genomics of lung adenocarcinoma: pathogenetic significance and clinical 
      applications.].
PG  - 652-672
LID - 10.1701/2502.26236 [doi]
AB  - Diagnostic and therapeutic approaches to non small cell lung cancer (NSCLC), 
      especially adenocarcinoma, have recently undergone dramatic evolution according 
      to the tremendous amount of molecular data collected on this cancer. In fact, the 
      application of oncogenomics has identified novel molecular subtypes of NSCLC and 
      led the way to diagnostic criteria based on the expression of specific genetic 
      alterations that can provide prognostic and specific indications to the molecular 
      targeted therapies. In NSCLC, several genes show "driver" molecular alterations 
      that confer oncogenic potential to progenitor cells through the enrollment of 
      metabolic pathways critical for cell proliferation and tumor development. On the 
      other hand, clinical management of NSCLC with small molecules has undoubtedly 
      provided optimistic results with both a significant increase in overall survival 
      and reduction in therapy-related toxicity including relative complications. Thus, 
      pharmacogenomics, as the newest tool for using the targeted therapy represents 
      the most innovative approach for treatment of this cancer once the molecular 
      aberrations are identified. In particular, the relative mutational status of 
      several driver genes including EGFR, ALK, ROS1 and others, is directly correlated 
      to a better response to thyrosin-kinase inhibitors. Furthermore, other 
      therapeutic strategies with inhibitors of angiogenic receptors, PARP, 
      histone-deacetylase, PI3K and HSP90, are intensively studied in pre-clinical 
      models as well as in clinical trials for a potential adoption in clinical 
      practice. The introduction of more advanced techniques for molecular profiling 
      also allows to identify pathogenic variants of many other genes involved in the 
      progression of lung adenocarcinoma with the aim to develop novel molecular 
      targets for pharmacological research. In this review, we will revisit the current 
      applications of oncogenomics in the diagnosis and treatment of this tumor.
FAU - Palmirotta, Raffaele
AU  - Palmirotta R
AD  - Dipartimento di Scienze Biomediche e Oncologia Clinica, Universita di Bari "Aldo 
      Moro".
FAU - Acquafredda, Silvana
AU  - Acquafredda S
AD  - Dipartimento di Scienze Biomediche e Oncologia Clinica, Universita di Bari "Aldo 
      Moro".
FAU - Argentiero, Antonella
AU  - Argentiero A
AD  - Dipartimento di Scienze Biomediche e Oncologia Clinica, Universita di Bari "Aldo 
      Moro".
FAU - Carella, Claudia
AU  - Carella C
AD  - Dipartimento di Scienze Biomediche e Oncologia Clinica, Universita di Bari "Aldo 
      Moro".
FAU - Lanotte, Laura
AU  - Lanotte L
AD  - Dipartimento di Scienze Biomediche e Oncologia Clinica, Universita di Bari "Aldo 
      Moro".
FAU - Pappagallo, Nicla
AU  - Pappagallo N
AD  - Dipartimento di Scienze Biomediche e Oncologia Clinica, Universita di Bari "Aldo 
      Moro".
FAU - Quaresmini, Davide
AU  - Quaresmini D
AD  - Dipartimento di Scienze Biomediche e Oncologia Clinica, Universita di Bari "Aldo 
      Moro".
FAU - Silvestris, Franco
AU  - Silvestris F
AD  - Dipartimento di Scienze Biomediche e Oncologia Clinica, Universita di Bari "Aldo 
      Moro".
LA  - ita
PT  - Journal Article
PT  - Review
TT  - Genomica dell'adenocarcinoma polmonare: significato patogenetico e applicazioni 
      cliniche.
PL  - Italy
TA  - Recenti Prog Med
JT  - Recenti progressi in medicina
JID - 0401271
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
SB  - IM
MH  - *Adenocarcinoma
MH  - Adenocarcinoma of Lung
MH  - Carcinoma, Non-Small-Cell Lung
MH  - Genomics
MH  - Humans
MH  - *Lung Neoplasms
MH  - Phosphatidylinositol 3-Kinases
EDAT- 2016/12/21 06:00
MHDA- 2018/05/09 06:00
CRDT- 2016/12/21 06:00
PHST- 2016/12/21 06:00 [entrez]
PHST- 2016/12/21 06:00 [pubmed]
PHST- 2018/05/09 06:00 [medline]
AID - 10.1701/2502.26236 [doi]
PST - ppublish
SO  - Recenti Prog Med. 2016 Dec;107(12):652-672. doi: 10.1701/2502.26236.